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A B S T R A C T   
An integrated model, based on a One Health approach, was implemented to estimate the epidemiological and 
economic outcomes of cystic echinococcosis (CE) in Veneto region, an hypo-endemic area of Northern Italy, and 
the costs for its prevention. Data and information needed to populate the model were retrieved from published 
literature, official statistics, expert opinions, or actively searched through data mining (i.e., Hospital and 
slaughterhouse data), when fundamental data were not available. Human-health and animal-health costs, both 
public and private, were considered. The overall impact of CE in the study area was estimated in an yearly cost of 
about 0.5 million €, due to an average of 19.5 human hospitalized cases and about 200 infected animals among 
cattle and sheep, per year. The human:animal costs ratio was about 8:1. Most of the infected animals were 
autochthonous, while the identification of an autochthonous source of the infection for the human cases was 
extremely difficult, and unlikely in most cases. No specific action resulted to be in place for human surveillance, 
while veterinary surveillance accounted for a yearly cost of about 22,000 €. Sheepherders were found to pay 
privately an overall amount of around 2000 € for the preventive treatment of their dogs every year, but the 
applied protocol proved to be sub-optimal. The source of most of the human cases was likely external to the study 
area, and their economic impact accounts for a cost that is far exceeding that of surveillance and preventive 
actions in place in the veterinary sector. Although autochthonous human cases appeared to be very rare, the 
strengthening of preventive actions and surveillance systems can reduce the risk of their increment.   
1. Introduction 
Evaluation in the domain of health is often mono-disciplinary, and 
tends to disregard the complexity of drivers and outcomes belonging to 
different scientific domains. In recent years, the methodological 
approach for the evaluation of health measures and policies is changing 
toward a more comprehensive vision of health-related problems [1]. 
The One Health (OH) concept is a shift in this context, as it looks at the 
consequences of human actions in all the sectors involved in health, 
according to a cross-sectoral approach [2]. The OH approach requires 
inter-disciplinary competences to understand the complexity of the re-
lationships between causes and effects. Evaluation also requires that the 
problem under analysis is an analytical unit (a system of relationships) 
relatively isolated from other systems. 
This study represents the outcome of a research project aimed at 
evaluating public/private health interventions to control cystic echi-
nococcosis (CE) in the Veneto region, North-Eastern Italy, to properly 
advise regional public health authorities. In Italy, regional health 
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authorities have an important role in defining disease control programs 
and implementing surveillance activities. This project implemented an 
innovative evaluation methodology to investigate where policy strate-
gies might be improved through a rational, cross-sectorial and inter-
disciplinary approach. The study area corresponded to the 
administrative territory of the Veneto region and CE was chosen as a 
case study, in consideration of its emerging nature in the area. 
Veneto is a region of North-Eastern Italy covering 18,345 km2, of 
which 43.6% are hills and mountains. In 2019, the population was 
4,907,704 inhabitants with an average Gross Domestic Product (GDP) 
per capita of 32,720 € (http://dati.istat.it/). The livestock sector is 
characterised by industrial farming, mainly for cattle (18,253 farms and 
757,700 heads estimated in 2019) and swine production (2053 farms - 
630,621 pigs in 2019), while forms of marginal and extensive husbandry 
dominate sheep and goat farming, with 73,359 and 26,336 heads esti-
mated in 2019, respectively, and an overall number of 5831 farms (https 
://www.vetinfo.sanita.it/). The ovine farming also includes trans-
humant sheep flocks with 500–1000 adult animals per flock that move 
continuously across the region throughout the year. An overall amount 
of 60 flocks were recently estimated [3], although this figure is including 
some flocks moving to Veneto plains, but registered in neighbouring 
regions. 
CE is a chronic and disabling disease in humans caused by the 
development of the larval stage of the cestode Echinococcus granulosus 
sensu lato (s.l.) [4]. In southern Europe, domestic ruminants (e.g. cattle 
and sheep) act as the main intermediate hosts for E. granulosus s.l., and 
domestic dogs are the main definitive hosts. The disease is particularly 
widespread in areas where traditional sheep herding still represents an 
important source of income [5,6]. Indeed, this kind of sheep farming is 
common in most areas of Central, Southern and insular Italy, which are 
considered hyper-endemic or endemic [7]. On the contrary, Northern 
Italy, which is characterised by a more industrialized livestock sector, 
was historically considered free from the disease or with a hypoen-
demic/sporadic presence. However, the epidemiological features of CE 
have recently gained attention in Veneto. Recent literature demon-
strated the circulation of the parasite in different animal populations [8] 
and reported records of human cases [9]; however the connection be-
tween circulation of the parasite in the animal populations and 
transmission risk to humans has not been investigated so far. 
2. Materials and methods 
2.1. Model building 
An integrated epidemiologic and economic model (EEM) and a data 
collection strategy were developed to better define, at regional level, the 
main characteristics of CE in the context of human, animal and envi-
ronmental health. The EEM was based on literature review and expert 
consultation, using an interdisciplinary approach reproducible for other 
contexts and diseases [10]. Briefly, the EEM was constructed thanks to 
the interaction between the research team (RT), composed by re-
searchers in economics, human health and animal health, and an 
interdisciplinary network (IDN) of professionals and scientists operating 
as an external advisory board, to validate the main outcomes of the 
model. The IDN members have been selected considering the integrative 
expertise needed to widen the RT institutional and operational 
perspective, in critical aspects of public health management, veterinary 
services implementation and One Health research. The first tentative 
model was submitted by the RT to the IDN members and the revised 
version was discussed and agreed between the RT and the IDN in a one- 
day meeting [10]. The model investigated the interrelations between 
epidemiology and health economics: the distribution and intensity of the 
infection in animals and humans could be evaluated in economic terms 
by joining the disease epidemiology with the economic functions. These 
interrelations were visualised using a flow chart (Fig. 1). 
The EEM was built to allow the identification of CE costs in the re-
gion and the type of data needed to develop the OH evaluation. The data 
to be collected were identified through the interactive process between 
RT and IDN and consisted in i) the number and anamnestic data of 
human CE cases; ii) the cost for clinical management and loss of pro-
ductivity of human cases; iii) the number of sheep and bovines found 
infected at slaughterhouse; iv) the costs related to offal condemnation 
and decreased productivity; v) the costs for preventive measures in an-
imals and humans. 
Fig. 1. Epidemiologic-economic model flowchart of cystic echinococcosis in Veneto (modified from [10]).  
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2.2. Data collection methodology 
2.2.1. Number and distribution of human cases 
The number of hospitalized human CE cases was obtained from 
Hospital Discharge Records (HDR), based on a dataset provided by the 
Italian Ministry of Health (MoH - protocol n. 23,875, date 06/08/2018) 
(Supplementary Material S1). All individuals, born in Italy or abroad, 
residing in Veneto and hospitalized in Italy between 2005 and 2016 with 
primary or non-primary diagnosis of echinococcosis (Codes 1220–1229 
of the International Classification of Diseases - Version 9 - Clinical 
Modification – ICD9CM) were included in the dataset [11]. Anonymized 
data on nationality, sex, age, living place (Municipality and Province), 
number of days of hospitalization, ICD9CM code, cyst localization, and 
type of clinical management (medical or surgical) of each admission 
were provided by the MoH and elaborated to display a simple statistical 
description of case distribution. Patients with multiple admissions were 
considered only once; furthermore, when different clinical manage-
ments (surgical and medical) were applied in different admissions, the 
patient was considered as only treated surgically. It was not possible to 
obtain data on CE cases diagnosed and managed as outpatients. CE in 
Italy is a notifiable disease not requiring single case reporting but only 
annual transmission of summary figures (number of cases seen in the 
year) to the regional health authorities which in turn should transmit 
these figures to the national health authority and from here at European 
level [12]. Unfortunately, this reporting system is not properly imple-
mented; therefore, de facto, the only available data on human CE in Italy 
come from hospitalized cases that are captured automatically by the 
HDR system. 
Autochthonous and non-autochthonous cases were differentiated 
mainly based on birth country and its endemicity for CE. For Italian 
patients, only young individuals (<30 years of age) living in a Munici-
pality included in a known cluster of bovine CE [8,13] were considered 
as suspected autochthonous cases. 
2.2.2. Cost of human cases 
The estimation of the economic impact of human CE was based on 
the evaluation of clinical management costs and productivity losses. 
Three types of relevant primary diagnosis of “echinococcosis” and 
respective clinical management protocols were considered: surgical 
treatment of hepatic echinococcosis; surgical treatment of thoracic 
echinococcosis; and hospital-based medical treatment of both hepatic 
and thoracic echinococcosis. As albendazole treatment does not require 
hospitalization, it can be speculated that these hospitalized but only 
medically treated cases represent patients with CE hospitalized for the 
purpose of in-depth diagnostic procedures (differential diagnosis, eval-
uation of treatment options, etc). For non-primary diagnosis of echino-
coccosis, it was possible to associate CE cases to a specific 
hospitalization cost if surgically treated, while solely the pre- and post- 
hospitalization costs were considered for the medically treated cases. 
The cases with undefined localization were attributed to hepatic or 
thoracic echinococcosis, in the same proportion as in the whole dataset. 
Hospitalization costs were deducted from the standard costs set by the 
Regional Health Authority for each type of diagnosis, identified by a 
specific Diagnosis Related Group (DRG) code [14]. By integrating hos-
pitalization costs with pre- and post-hospitalization medical procedures, 
we defined standard procedures for each relevant type of treatment and 
assigned a unit cost to each step of the process. Clinicians from the 
reference hospital for Tropical Diseases in Veneto (Sacro Cuore Don 
Calabria, Negrar, Verona), involved in the management of patients with 
CE, were asked to delineate common features of the clinical manage-
ment of patients undergoing different treatment procedure, from the 
diagnostic process to the follow-up. Features requested to the experts 
included types of exams prescribed for the diagnosis of CE (e.g. serology, 
imaging); dose and length of drug prescription in relation with the 
defined medical or surgical management; and type and frequency of 
exams to be performed during the recommended treatment and follow- 
up (e.g. imaging, blood test to monitor side effects of the drugs). The 
clinicians involved in the definition of the standard procedures apply in 
their setting the recommendations of the WHO Informal Working Group 
on Echinococcosis (WHO-IWGE) [15]. Standard procedures allowed the 
identification of costs for health care services supported by public in-
stitutions and private individuals, and patients' productivity losses. The 
costs for health care services supported by public institutions correspond 
to the reimbursements paid by the regional administration to hospitals 
and laboratories delivering such services. Costs for health care services 
supported by private individuals were the patients' out-of-pocket ex-
penditures integrating the regional payments for some medical services 
(i.e. participation in the cost of some analyses; cost of drugs not reim-
bursed by the public health administration). The patients' loss of pro-
ductivity consists in the time lost for medical visits, hospitalization, and 
convalescence. Cost calculation applied the transformation of the cur-
rent available monetary data into 2019 euros (€2019). We adopted 
standard costs established by the Veneto Region in 2011 [14], then 
translated in the corresponding values of 2019 by applying the national 
consumer price index (Italian national Institute for Statistics - ISTAT, 
https://www.istat.it/it/archivio/30440). All values were provided by 
the Sacro Cuore Don Calabria hospital administration (reference centre 
for Tropical Diseases in Veneto) and established by the regional law 
[14], also concerning the contribution requested from private 
individuals. 
The unit cost of productivity losses due to human CE was calculated 
by assigning different percentages of temporary disability according to 
the type of disease management (surgical or medical). Disability weights 
and their duration (up to 5 years) for abdominal and thoracic CE were 
deduced from the available literature [16,17], converted into working 
time losses, and then into monetary values. In details, a disability weight 
of 0.8 for the first month, 0.2 for the first year [16] and 0.1 for the 
following four years [17] were used for surgical interventions, while 
disability weights of 0.1 for the first six months and 0.01 for the first five 
years [17] were adopted for medical management. Productivity losses 
were estimated by multiplying the above-mentioned rates (disability 
weights - DISw) for the GDP/inhabitant/working day (GDPwd) and for 
the number of days (WDav) lost because of the illness (for each of the 
identified sickness periods), according to the formula: productivity los-
ses = DISw*WDav* GDPwd. The GDPwd was obtained dividing the 
average GDP/inhabitant in the Veneto Region during 2005–2016 
(GDPav) by the average number of working days during 2005–2016. The 
GDPav was calculated transforming the annual regional GDP/inhabitant 
into €2019 value, and multiplying the annual data by the corresponding 
monetary transformation index (both data available at the ISTAT web-
site, resulting respectively from on line queries and historical tables of 
monetary transformation indexes - http://dati.istat.it/) and calculating 
the average of this new €2019 series. The annual WDav resulted from the 
average of the annual working days during the considered period. 
Annual working days are available at https://api.workingdays.org/1. 
2/api-countries.php. The number of annual working days is rather sta-
ble during the period (average: 253, min÷max: 250÷254). The number 
of WDay for each considered periods were calculated dividing the 
annual average by the appropriate rate (e.g. one month Wday = annual 
Wday/12). 
2.2.3. Number and distribution of cases in livestock 
The number of slaughtered bovines and sheep in the Veneto region 
were obtained from the veterinary National Information System (https 
://www.vetinfo.sanita.it/) for the years 2014–2017 (Table 1 and Sup-
plementary Material S3). 
To estimate the number of infected bovines we relied on the infection 
rate calculated in a previous 5-years investigation, which was consid-
ering only dairy cows, since beef calves and bulls showed an irrelevant 
number of cases [13]. A correction was applied to the prevalence esti-
mate, since it was calculated based on ISTAT data (http://dati.istat.it/), 
which consider only the animals slaughtered in the Region and do not 
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include the Veneto's livestock slaughtered outside the Region. Based on 
this calculation, the value (0.33%) reported in [13], was converted in a 
prevalence estimation of 0.17% (95%CI: 0.16–0.19%) (Table 1). 
Since there was no available data concerning CE prevalence in sheep, 
the number of adult sheep with echinococcal cysts was estimated 
through a survey conducted in a selected group of slaughterhouses. All 
the units slaughtering more than 100 adult sheep yearly were contacted 
to obtain the estimated infection rate of sheep at inspection. Totally, 11 
sheep slaughterhouses (5 outside and 6 in Veneto) were contacted and 7 
replied (of which 3 in Veneto), providing data for one or more years (see 
S3 for details). Only adult sheep (>1 year) were considered, whereas 
younger sheep were not included in the analysis, since the data for this 
category were provided in an aggregated form (slaughtered lambs 
coming from a single farm were registered collectively as a group, 
without specifying their number). However, these animals have gener-
ally a very low prevalence of infection, due to the low probability of 
acquiring the infection and presenting a developed CE cyst within the 
first months of life. 
2.2.4. Cost for offal disposal and loss of productivity in animals 
Offal disposal and productivity losses of infected animals were 
considered for the estimation of the economic impact of CE on animal 
production. 
The economic loss for offal condemnation is the foregone income due 
to unsold products and cost of organ destruction, which has to follow 
specific protocols, if the organ is declared infected. As per the foregone 
income of infected organs at slaughter, only bovine livers were consid-
ered, since bovine and ovine lungs and ovine livers have little or no 
economic value in the study area. Unit values for organ weights and 
relevant costs were retrieved from available literature [18–20] and 
official statistics. The available monetary data were transformed into 
€2019 values (Table 1). 
The calculation of the economic impact on animal productivity 
included the losses from reduced weight gain in sheep and reduced milk 
production in cows. Indeed, milk-producing sheep in Veneto repre-
sented only the 2.7% (1966/73,359) of the total sheep heads in the 2019 
in Italy (https://www.vetinfo.sanita.it/), whereas almost all affected 
bovines were dairy cows. Historical series of the amount and prices of 
livestock production in Veneto were obtained from official statistics 
(Table 1). Indicators of productivity losses, were deduced from the 
available literature [21]. The average/intermediate value, the uncer-
tainty and the source of all parameters used in the model for animal costs 
are reported in Table 1 and the formulas to calculate the overall costs for 
offal disposal and loss of productivity are reported in Table 2. 
2.2.5. Actions in place to prevent infection spread 
The estimation of the overall costs for preventive health measures 
included the resources spent for veterinary surveillance activities and 
Table 1 
Parameters used in the model to calculate the costs for animal component. Parameters obtained from official statistics and data mining were calculated using the period 
2014–2017.  




Interval Description of lower and 
upper values calculation 
Ratio of difference between 
upper and lower values 
compared to the average 
Source of data 
Lower Upper 
CE prevelence in 
dairy cows 
CEbprev 0.17% 0.16% 0.19% avg + − 2*SE 0,18 [13]1 
CE prevalence in 
sheep 
CEoprev 6.05% 5.1% 7.0% avg + − 2*SE 0,31 This study - data 
mining 
N slaughtered dairy 
cattle 
Nbsl 59,355 54,488 64,222 avg + − 2*SD 0,16 National 
Information 
System2 
N slaughtered adult 
sheep 
Nosl 2574 917 4231 avg + − 2*SD 1,29 National 
Information 
System2 




Cost of offal disposal Kdisp 0.44 €/kg 0.44 €/kg 0.44 €/kg Fixed value 0 [19] 
Price of raw milk Pmilk 40.36 €/hl 34.05 €/hl 46.68 €/hl avg + − 2*SD 0,31 Verona market, 
Veneto4 




Bovine liver weight Wbli 5.86 kg 4.18 kg 7.54 kg avg + − 2*SD 0,57 [18]6 
Bovine lungs weight Wblu 3.34 Kg 2.18 kg 5.50 kg avg + − 2*SD 0,99 [18]6 
Reduction in milk 
production in 
bovines 
Lmilk 7.3% 2.5% 12.0% Provided in the source of 
data 
1,30 [21] 








avg + − 2*SD 0,10 ISTAT7,8 
Ovine lungs weight Wolu 0.72 Kg 0.72 Kg 0.72 Kg Fixed value 0 [20]9 
Ovine liver weight Woli 0.45 Kg 0.45 Kg 0.45 Kg Fixed value 0 [20]9 
Reduction in growth 
in ovine 
Lmeat 11.3% 2.5% 20.0% Provided in the source of 
data 
1,55 [21] 
Dead weight of adult 
sheep carcass 
Qmeat 27.2 kg 22.0 kg 32.4 kg avg + − 2*SD 0,35 ISTAT7  
1 Corrected considering an estimated denominator of 266,880 (142,488 × 1.873). 142,488 is the denominator used in [13] and 1.873 is the by the ratio between 





6 transformed according to ratio 1 kg = 0.4536pound. 
7 http://dati.istat.it/ 
8 In hectolitres, using 0.971 as conversion rate from 100 Kg (q) to 100 l (hl) 
9 Variability estimates not provided. 
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for the periodic treatment of dogs at risk of infection. Regarding veter-
inary surveillance, no structured official plan is adopted by the Region: 
passive surveillance procedures, based on the general indications of 
Directive 2003/99/EC, are implemented by the nine Local Health Au-
thorities (LHAs) operating in the Veneto region. A structured question-
naire was submitted to veterinarians in charge of CE surveillance in all 
LHAs to obtain information on the current procedures for the manage-
ment of bovine and ovine cases in the Region, and time allocation for 
each phase of the procedure. The answers received by eight of them 
were summarized in a flow diagram (Fig. 2) and in the related 
description of each phase of the procedure. Cost estimation was based on 
standard costs for veterinary services provided by LHAs [22] and on 
standard costs applied to laboratory analyses by the Regional Laboratory 
in charge of animal health surveillance, i.e. the Istituto Zooprofilattico 
Sperimentale delle Venezie (IZSVe - https://www.izsvenezie.it). All 
costs were converted in €2019. 
The estimation of the costs for the periodic treatment of dogs was 
aimed at identifying the overall costs for the hypothetic scenario of an 
appropriate treatment protocol applied to all dogs at risk, and the real 
scenario of the treatments actually in place. Sheep dogs were identified 
as the dogs at risk of infection, and their number was obtained thanks to 
relevant literature [3,8]. The canine population was estimated in 258 
sheep dogs, based on the presence of about 60 transhumant sheep flocks 
living in or passing throughout the region [3] and an average number of 
4.3 dogs per flock [8]. 
An average market price for praziquantel-based drug available in the 
Italian market was estimated based on information provided by a retail 
franchise of pet supplies. In consideration of the high variability in 
weights among dogs, the average dose was assumed to correspond to 
that for a 15–20 kg dog. 
To calculate the overall cost for both scenarios, the price of a treat-
ment with anthelmintic drug (i.e. praziquantel) was multiplied by the 
number of administrations performed in a time unit (one year), and by 
the estimated number of treated dogs in Veneto, according to the 
following formula: 
Kdog = Padmin* Nadmin* Ndog (6)  
where: 
Kdog = overall yearly cost of dogs' preventive treatment. 
Padmin = average price of one administration of appropriate drug 
(€2019/dose). 
Nadmin = number of administrations per year. 
Ndog = number of dogs treated. 
Regarding active surveillance (e.g. ultrasound surveys) and preven-
tive measures in humans (e.g. specific health education campaigns), 
these were not included in the EEM, as no such activities are imple-
mented in the study area. 
2.3. Uncertainty and data synthesis 
To account for the uncertainty, the intermediate estimates, the lower 
estimates (best-case scenario) and the upper estimates (worst-case sce-
nario) of each parameter were included in the model and displayed, 
whenever possible. The 95%CI lower and upper values of the parameter 
distribution were considered as the lower and upper estimates (i.e. 
calculated prevalence ±2*Standard Error for sample-based prevalence 
values; average ± 2*Standard Deviation for quantitative parameters). In 
some cases, parameters were considered fixed, if determined by local 
legislative acts (e.g. for medical costs supported by the regional health 
Table 2 
Formulas to calculate the costs for offal disposal and loss of productivity (all 
formulas refer to one-year timespan).  
Costs Cattle Sheep 
Foregone income 
due to unsold 
livers 
(1) KB1 = Nbsl * CEbprev * 
Wbli * Pbl 
– 
Cost of organ 
destruction 
(2) KB2 = (Wbli + Wblu) * 
Kdisp * Nbsl * CEbprev 
(4) KO1 = (Woli + Wolu) * 
Kdisp * Nosl * CEoprev 
Loss in milk 
production 
(3) KB3 = Qmilk * CEbprev * 
Lmilk * Pmilk 
– 
Loss due to reduced 
growth 
– (5) KO2 = Qmeat * CEoprev * 
Lmeat * Pmeat 
Notes Nbsl = nr of slaughtered 
dairy cows 
Wbli = weight of bovine 
liver (kg) 
Pbl = price of bovine liver 
(€/kg) 
Wblu = weight of bovine 
lung (kg) 
Kdisp = unit cost of disposal 
(€/kilo) 
Qmilk = yearly bovine milk 
production (hl) 
CEbprev = prevalence of CE 
in dairy cows (%) 
Lmilk = loss of milk 
production in infected 
cattle (hl) 
Pmilk = price of bovine 
milk (€/q) 
Nosl = nr of slaughtered 
adult sheep 
Woli = weight of ovine liver 
(kg) 
Wolu = weight of ovine lung 
(kg) 
Kdisp = unit cost of disposal 
(€/kilo) 
Qmeat = weight of ovine 
carcasses (kg) 
CEoprev = prevalence of CE 
in sheep (%) 
Lmeat = loss of meat 
production in infected sheep 
(kg) 
Pmeat = price of sheep meat 
(€/kg)  
Fig. 2. Flow diagram of the procedure in place for veterinary surveillance of CE in the Veneto region. CE = cystic echinococcosis. LHA = Local Health Authorities.  
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system), or if based on literature data, when the published paper was not 
reporting any uncertainty value. The number of hospitalized human 
cases was also considered as actual and certain, but the interannual 
variability was taken into account to determine the variability sur-
rounding the estimation of their annual costs. 
In the final step of data analysis, all collected data were summarized 
in a new flow chart to visualise the different contributions each 
component was bringing to the overall burden of the disease, and their 
relative uncertainty interval. This exercise was aimed at supporting 
decision making for cost-effective health interventions. 
3. Results 
3.1. Impact of CE on human health 
A total of 234 residents of the Veneto region (90 Italian-born and 144 
foreign-born) were admitted to hospitals and treated for CE in the study 
period, with a mean of 19.5 cases per year (95%CI: 9.1–29.9) and 
without any clear decreasing or increasing trend over time. Considering 
the total population of the Region as population at risk, we could 
therefore estimate an incidence rate of hospitalized cases of 0.4 cases/ 
100,000 people per year (95%CI: 0.2–0.6). The cases were similarly 
distributed between sexes, with 121 males (52%) and 113 females 
(48%). Only 8% (19/234) were young individuals (≤20 years), the 
majority (166/234, 71%) were aged between 21 and 60 years, and the 
remaining (49/234, 21%) were over 60 years of age. Some cases were 
recorded as alveolar echinococcosis (ICD9CM 1225–1227). However, in 
Italy only CE is endemic, while no autochthonous or imported cases of 
human alveolar echinococcosis (AE) are currently known [23]. Based on 
the epidemiological situation of AE in the countries of origin of these 
patients that is absent or extremely rare [24], and on the highly unlikely 
fact that a true diagnosis of AE in Veneto would have been posed without 
the assistance for its diagnosis and complex clinical management of the 
regional referral centre, we considered that they were CE cases with 
multi-loculated cyst appearance, e.g. 2CE or CE3b stages of the WHO- 
IWGE classification [15]. The distribution of human cases according to 
cyst localisation and type of clinical management is reported in Table 3 
(S1 for details). 
The majority of cases (129/234, 55%) were treated surgically, 
whereas 105 patients (45%) received medical treatment as sole inter-
vention. For 177/234 (76%) cases, CE was a primary diagnosis. 
Considering only cases with a single hospitalization (n = 136), the 
estimated mean number of days of hospitalization was 13.8 days for 
surgical and 10.9 days for medical management. 
Standard DRG reimbursement for one hospitalized CE case ranged 
from 2793 to 10,736 €2019 depending on cyst localisation (liver or lung) 
and type of treatment. However, including pre- and post-hospitalization 
and loss of productivity, a single human CE case would cost between a 
minimum 6959.84 €2019 and a maximum 35,354.98 €2019 (Table 4 and 
S2 for details). When considering all cases recorded as CE-related HDR 
(S2 for details), the total cost for the Veneto region in the period 
2005–2016 was estimated to reach 5,313,506.13 €2019 (4,392,292.55 
€2019 for surgical treatments and 920,213.58 €2019 for medical treat-
ments), for a yearly mean of 442,792.18 €2019 (95%CI: 170,074.32- 
715,510.03 €2019). 
The estimate of the relative percentage of autochthonous and non- 
autochthonous human CE cases was difficult to achieve. Foreign-born 
patients (144/234, 61.5%) were mostly from countries endemic for CE 
(e.g. Morocco = 55; Romania = 29; Moldova = 14; North Macedonia =
8; Tunisia = 7) and therefore we assumed that the infection was most 
likely acquired in their country of origin. Concerning Italian-born pa-
tients (90/234, 38.5%), our data did not allow understanding if patients 
were born in Veneto or in other Italian regions (possibly endemic for CE) 
and for how long they had been residing in Veneto. Out of 5 persons 
under 30 years of age, it was possible to identify only one case, a 20-year 
old female living in a municipality included in a cluster of bovine CE 
identified in 2014 [8], who we classified as autochthonous case. 
3.2. Impact of CE on animal health 
An average of 59,355 dairy cows (95%CI: 54,488-64,222) raised in 
the region were slaughtered yearly in the period 2014–2017. Consid-
ering an estimated prevalence of 0.17%, 101 infected animals (95%CI: 
87–122) were estimated to be found in the region each year. As per 
ovines, an average of 2574 adult sheep (95%CI: 917–4231) belonging to 
farms based in Veneto were slaughtered yearly in the period 2014–2017. 
The estimated infection rate of CE in slaughtered sheep was 6.0% 
(CI95% 5.1%–7.0%). Consequently, an overall average of 156 sheep 
(95%CI: 47–296) were estimated to be infected on a yearly basis (see S3 
for details). 
The overall cost for offal condemnation and production losses were 
calculated according to Table 1 parameters and Table 2 formulas (see S3 
for details). An average annual economic impact of 53,282.75 €2019 
(lower estimate: 14,345.45; upper estimate: 119,312.26) was estimated, 
mostly attributable to loss in milk production from infected dairy cows 
(Table 5). 
As per definition of the percentage of autochthonous cases, the 
movements tracking system in place for sheep did not allow for a certain 
identification of the most likely origin of the infection, although most 
sheep raised in Veneto should be considered locally born, according to 
expert opinion. Concerning bovines, according to previous data [13], 
81.1% of cattle found positive for CE in Veneto were autochthonous. 
3.3. Cost of preventive measures in place 
The costs of the procedures currently in place in the Region for 
veterinary surveillance (flow diagram in Fig. 1) were calculated for 
bovine farms, whereas LHAs reported that sheep CE cases are never or 
rarely notified. A description of the activities, time allocation and 
associated costs of the four procedural steps of the surveillance pro-
cedure are shown in Table 6. 
The average cost for each bovine CE case resulting in a complete farm 
survey (including samples collection and analysis) was 275.43 €2019. In 
some cases, the procedure can be concluded at step 2 (Fig. 2 and 
Table 6), when the analysis of animal tracking suggests that the farm of 
origin found in Veneto cannot be the source of the infection. Therefore, 
considering the estimated implementation rate of each step (Table 6), an 
average cost of 203.54 €2019 was obtained. Considering that 101 cattle 
(95%CI: 87–122) are yearly notified to the veterinary services, the 
overall yearly costs for veterinary surveillance amount to 21,778.78 
€2019 (lower estimate: 17,707.98 €2019; upper estimate: 24,831.88 
€2019). 
The overall cost for preventive treatment of dogs at risk for the two 
scenarios (appropriate protocol for all dogs at risk; prevention treat-
ments actually in place) and parameters for their calculation are shown 
in Table 7. The unit cost of an appropriate yearly preventive treatment 
was considered to amount in at least 4 treatments a year for one dog and 
it was therefore estimated in 32.00 €2019. However, the current practice 
Table 3 
Number of hospitalized human CE cases according to localization of the cyst 
(undefined, liver, lung) and type of management (surgical, medical) in the 
Veneto region in the period 2005–2016.  
Diagnosis Localisation Type of clinical management Total 
Surgical Medical 
Primary Undefined 17 16 33 
Liver 99 37 136 
Lung 4 4 8 
Non-primary Undefined 1 16 17 
Liver 8 31 39 
Lung  1 1 
Total 129 105 234  
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adopted in the Veneto region does not correspond to an appropriate 
preventive protocol. According to literature [8], 48% of sheep dogs were 
treated about two times per year, whereas the remaining ones were not 
treated or treated with unknown periodicity. These preventive treat-
ments are paid by dog owners (private cost). 
The total yearly expenditure actually supported by sheepherders for 
dog treatments was estimated at 1981.44 €2019, but an appropriate 
preventive protocol for the whole sheep dog population would imply a 
yearly cost of 8256.00 €2019. 
3.4. Data synthesis 
The overall annual economic impact of CE in the study area was 
estimated at an average of 496,074.93 €2019 (95%CI: 184,419.77- 
834,822.29 €2019). Fig. 3 depicts the flow chart developed during the 
first phase of the project [10], filled with the numbers retrieved during 
the second phase, and summarizing the epidemiological and economic 
outcomes of CE in the study area. 
As highlighted in Fig. 3, the economic impact of the relatively few 
human cases is about eightfold higher than the costs related to the an-
imal component, which are mainly due to the reduced milk production 
by infected dairy cows. The preventive measures in place at present in 
Table 4 
Cost structure of CE clinical management protocols in Veneto region (€2019).  
Description of clinical management protocol (DRG code) Hospitalization cost Pre- and post-hospitalization costs Loss of productivity Total costs 
(public) (public) (private) 
Abdominal surgery of liver CE (DRG 192) 8464.29 665.86 393.97 24,583.51 34,107.63 
Thoracic surgery of lung CE (DRG 075) 10,736.06 181.15 242.62 24,195.15 35,354.98 
Medical treatment of CE - primary diagnosis (DRG 423) 2792.57 1167.69 707.80 5615.11 10,283.18 
Surgical treatment of CE - non-primary diagnosis (DRG 468) 7083.20 665.86 393.97 24,583.51 32,726.54 
Medical treatment of CE - non-primary diagnosis – 1167.69 707.80 5084.35 6959.84  
Table 5 
Yearly average number of infected animals and consequent yearly economic losses due to CE in cattle and sheep (€2019).   
Infected animals 
(N) 
Costs (€2019) Total 
Foregone income due to unsold 
livers 
Cost of organ 
destruction 
Loss in milk production Loss due to reduced 
growth 
Average Average Average Average Average Average 
Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper 
Cattle 101 1673.36 408.46 50,634.74   52,716.56 
87 122 867.66 3.017.06 243.99 646.40 13,184.76 113,442.71   14,296.40 117,106.17 
Sheep 156  80.09   486,10 566.19 
47 296   24.08 152.48   24.96 2053.62 49.04 2206.09 
Overall     53,282.75           
14,345.45 119,312.26  
Table 6 
Details of cost estimation of the four steps of veterinary surveillance procedure for the management of a bovine CE case (€2019).  








1 CE case notification at 
slaughterhouse 




No specific time 
allocated 
37.96 0.5342 20.27 
Communication to LHU 30 
2 Data analysis and interpretation Database investigation Personnel time 
(veterinarian) 
35 44.29 1 44.29 
Database updating and data 
transmission 
3 Farm survey (outbreak 
investigation) and samples 
collection 
Round trip to the farm 
(standard cost) 









Drug prescription to farm dogs 
Faecal sampling of farm dogs 
4 Laboratory analysis Standard analytical procedure All-embracing fixed 
cost 
€ 58.875 58.87 1.185 
(0.515*2.3)6 
69.76 
Total 275.53  203.54  
1 Minutes, if not otherwise indicated. Unit cost for one minute of LHU personnel (veterinarian) is 1.27 €2019, calculated on a one-hour standard cost of 74,00 € [22] 
and transformed into €2019. 
2 Rate of dairy cattle slaughtered in the Veneto region on total slaughtered (see S2 for details). 
3 Official Veneto Region standard cost (€ 20.00) for LHA services car usage [22] and transformed into €2019. 
4 The rate is calculated considering the non-autochthonous cases (− 18.9%) according to [13] and the repeated cases, i.e. the cases coming from the same farm (−
36.5%) [13]. The rate is calculated thus as: (1–0.189)x(1–0.365) = 0.515 (51.5%). 
5 Official standard costs applied to laboratory analyses by IZSVe (i.e. coprologic isolation of Taenidae - CPRTAE = 21.96 €; qualitative coprologic examination - 
CPRQL = 9.97; PCR + Sequencing of Cestoda - ARCEST = 26.94 €). 
6 The rate is calculated multiplying the above rate for investigated farms by the average number of dogs found in a bovine farm [8]. 
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the region account for about 24,000.00 €, mostly attributable to the 
veterinary surveillance activity. 
4. Discussion 
The findings of the present study allow for an improved under-
standing of the impact of CE in the study area, laying the foundations for 
an evidence-based decision-making process on the measures to control 
this disease. The analysis of the HDRs showed an estimated incidence 
rate in the human population of 0.4/100,000 people per year, which is 
in line with what already reported for northern Italy and for other hypo- 
endemic regions in wealthy and industrialized economies [7,9,25]. 
More importantly, our findings suggested that the source of the infection 
for most of the human cases is external to the study area, although few 
cases were possibly autochthonous. Concerning animals, this study 
attempted for the first time to estimate the prevalence of CE in sheep in 
the study area (estimated at 6.0%). Prevalence estimation in sheep based 
on slaughterhouse records are difficult to achieve in Italy, due to the lack 
of an efficient data flow from slaughterhouse to LHAs. Our finding is 
slightly exceeding the value predicted for sheep farm prevalence in the 
Veneto region in a recent study [26], which was however including also 
young animals in the denominator, among slaughtered sheep. The 
calculated prevalence value for CE in cattle (0.18%) is in line with values 
reported in other regions of Northern Italy [27,28]. 
The overall economic impact of CE in the region is less than 0.5 
million €2019, as expected in a hypo-endemic area. A similar total cost 
(483.608,00 €) was estimated in the year 2004 for Lombardy (8,410,374 
inhabitants), a region neighbouring Veneto [28]. However, that study 
considered only hospitalization costs for human cases. There are many 
studies on the economic impact of CE in developing countries with low- 
middle income [29–32], which are generally estimating an overall 
yearly cost of a few millions US$ for entire countries, such as Jordan and 
Peru, or a few hundred thousand US$ for areas with smaller populations, 
such as the Tibetan Plateau. Only a few studies were conducted in re-
gions or countries with socio-economic conditions similar to our study 
area. In Spain, an overall economic impact of about 150 million € was 
estimated in 2005 [33], meaning a monetary estimation 300 times 
higher than that obtained in the present study. This difference depends 
on the different size of the considered study areas (about 43 million 
inhabitants in Spain in 2005 vs 5 million in Veneto) and can be partly 
due to the higher incidence of hospitalized human CE cases recorded in 
most regions of Spain [7], compared to Veneto. Besides, this study 
included different costs (reduction in carcass weight, reduction in milk 
production and decrease in fecundity) associated to four domestic spe-
cies (sheep, goats, cattle, pigs). In Wales (2,900,000 inhabitants), the 
total annual cost due to CE in 1997 was estimated to range from about 
1000,000 US$ to about 6,700,000 US$ [25], which is anyhow propor-
tionally higher than our estimation for Veneto. One important difference 
for the case of Wales lies on the higher contribution provided by animal- 
health costs that are more than threefold higher than human-health 
costs. In this study, reduction in carcass and fleece values and reduc-
tion in fecundity associated with sheep were considered. According to 
our results, on the contrary, the relatively few human cases occurring in 
residents in Veneto imply an important cost (about 443,000 €/year) for 
Table 7 





actually in place 
Price (€/tablet)1 € 4,00 € 4,00 
Average nr of tablets/dog 2 2 
Nr admin/year 4 2  
Cost of treatment of 1 dog/ 
year 
32,00 € 16,00 € 
Overall nr of dogs at risk 258 258 
Percentage of treated dogs 
(among the ones at risk) 
100% 48%  
Overall cost for dog 
treatment/ year 
€ 8.256,00 € 1.981,44  
1 Average price for 1 tablet of praziquantel-based drug, according to infor-
mation provided by a retail franchise of pet supplies and available in the web. 
Fig. 3. Flow chart reporting the main epidemiological and economic outcomes of CE in the Veneto region, on an annual basis. 
Note: The black arrows represent the causative flows, and their size is proportional to the relative importance of each flow; the dotted line indicates an undem-
onstrated causative flow. Coloured lines link each specific preventive measure to the stage of the parasite life cycle targeted by the intervention. 
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the regional health system and the overall economy of the Region. The 
impact of the disease in animals instead was not very relevant (about 
53,000 €/year), and mostly due to reduced milk production in cattle. 
The human:animal costs ratio is about 8:1, which is therefore the 
opposite to what found in Wales [25], but similar to Spain [33]. 
Our study highlighted a number of limitations in the attempt to 
achieve a detailed estimation of the economic impact of the disease. 
Firstly, non-hospitalized human CE cases not captured by the HDR 
system were not retrievable. Therefore, the number of human cases 
medically treated or managed by watch-and-wait (patients with 
asymptomatic, inactive CE undergoing only regular control with imag-
ing), and consequently the derived costs estimations, are under-
estimated. Also, due to the rarity of life-long disability caused by CE, for 
example in case of osseous involvement, and the absence of such cases in 
the examined dataset, this instance was not considered in our EEM. 
Finally, we could not estimate, and therefore quantify costs related to 
the proportion of infected patients with some disability due to symptoms 
who are not diagnosed (as having CE or at all). 
The lack of active surveillance and control activities for the human 
component complicated the estimation of epidemiological and eco-
nomic outcomes. However, this is partly justified by the nature of the 
disease in humans, who are a dead-end host for the parasite. Therefore, 
human case management does not impact parasite transmission cycle to 
either animals or humans; that is, does not prevent further human cases. 
Early diagnosis and treatment of human CE, ideally achieved through 
active surveillance, may reduce the cost of infection, as more cases could 
be managed by medical therapy only. However, active surveillance of 
CE cannot be implemented through serology [34], and regular screening 
by imaging (abdominal ultrasound and chest X-ray) should be carefully 
evaluated in the light of cost-benefit analyses in an area of very low 
endemicity and compliance with principles for disease screening [35]. 
Finally, although we elaborated a case definition to identify 
autochthonous cases, the origin of the majority of the human infections 
remains uncertain. Most cases were probably imported, and only one 
human case (0.4%) in the whole observation period was strongly sus-
pected to be autochthonous. The identification of the autochthonous 
nature of human cases can be attempted, if at all, only at the time of the 
anamnestic interview and therefore clinicians should receive appro-
priate training on this emerging infection, including a knowledge update 
on the local epidemiology of E. granulosus s.l. in animals. However, an 
accurate epidemiological tracking of the source of human infections, 
similar to what implemented in livestock farms, is almost always 
impossible because no acute signs of infection occur, and the vast ma-
jority of human CE cases have a slow cyst development and remain 
asymptomatic for a very long time. 
As per Directive 2003/99/EC on the monitoring of zoonosis and 
zoonotic agents, regional and local health authorities built up a quite 
complex monitoring system for bovine CE, targeting the infected inter-
mediate animal hosts and aimed at identifying the source of the infec-
tion. These preventive measures account for a cost of about 22,000 €2019 
per year; however, their efficacy in controlling the disease is under 
question and a new approach to the management of CE cases in cattle 
was already proposed, since the bovine farm dogs were very rarely 
found to be the source of the infection [8]. On the contrary, the tracking 
system for sheep CE appeared to be inefficient, and there was a general 
lack of data on sheep infection at slaughterhouse. In fact, most LHAs 
declared that they did not receive any notification of CE from slaugh-
terhouses, notwithstanding the 6.0% prevalence in sheep reported 
directly by slaughterhouse officials in response to our active data 
request. Furthermore, this data relies on the answer received by only 
part of the slaughtering facilities actively contacted (63.6%) and 
therefore the estimated infection rate may suffer of a bias due to this. 
The surveillance system in animals and more specifically in sheep needs 
therefore an improvement, and data reporting to LHAs has to be uni-
formly assured by all slaughterhouses in and outside the Veneto region. 
Preventive measures implemented by private citizens (treatment of 
sheep dogs) accounted for a limited cost (about 2000 € per year). 
However, the treatment protocols applied by shepherds proved to be 
sub-optimal, consisting of an average of two administrations per year (or 
less), while the recommended protocol should ideally rely on one 
treatment every six weeks, and realistically aims for four treatments per 
year. A public support to cover the cost of the drugs for sheepherders can 
account for about 8500 €/year. However, this action needs to be asso-
ciated to the implementation of specific training for sheepherders and a 
new system to monitor the regular treatment of sheep dogs. 
Finally, although the picture drew in the present study allowed for an 
overall estimation of the importance of CE in the study area, our EEM 
did not consider the contribution that could be provided by other do-
mestic (e.g., goats, pigs) and wild (e.g., wolf, wild ruminants) animals. 
Their role was considered negligible during the building of the EEM 
[10]; however, this situation may change in the future, considering the 
dynamic nature of many ecological and social phenomena (e.g. the 
epidemiological role of the wolf can increase in the future, in consid-
eration of his recent colonisation of the study area). 
5. Conclusion 
CE annual economic impact in the Veneto region is mostly due to 
human-health costs and amounts to about 0.5 million €2019. The eco-
nomic impact of the relatively few human cases is about sevenfold 
higher than the costs related to the animal component, which are mainly 
due to the reduced milk production in infected dairy cows. The source of 
most of the human cases was likely external to the study area and this 
finding suggests that locally implemented preventive actions have a 
limited impact on the reduction of the burden of the disease. However, 
considering that a surgically treated case can account for an overall cost 
exceeding 30,000 €, even few autochthonous cases can imply an annual 
cost for the regional economy that is by far exceeding the overall yearly 
cost of preventive actions on animals. Thus, an improvement in the 
veterinary surveillance system (including the data flow management) 
can allow the early identification of emerging clusters of local parasite 
circulation, preventing the risk for an increment in the number of 
autochthonous human cases [36,37]. 
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